<DOC>
	<DOCNO>NCT01585870</DOCNO>
	<brief_summary>This Phase 1 study conduct open-label , non-randomized , dose-escalation design subject advance , metastatic refractory solid malignancy candidate standard therapy . The study drug sorafenib eribulin mesylate . Up 24 subject solid tumor participate dose escalation part study , maximum tolerate dose define , 30 subject advance , metastatic refractory solid tumor participate expansion phase study . Eribulin ( mesylate ) administer intravenously fix dose 1.4 mg/m2 Days 1 8 21-day Cycles . The start sorafenib dose ( Dose Level 1 ) 200 mg twice daily . Sorafenib give orally , continuously day 11 21 Cycle 1 , Day 1 Day 21 subsequent cycle . If 200 mg sorafenib twice daily tolerate eribulin , sorafenib dose escalate sequentially 200 mg morning dose 400 mg even dose ( Dose Level 2 ) new cohort . If Dose Level 2 tolerate , second dose escalation 400 mg twice daily ( Dose Level 3 ) study new cohort . If start dose sorafenib tolerate eribulin , sorafenib dose de-escalated 200 mg daily new cohort . Subjects need receive two cycle eribulin plus sorafenib therapy safety data first second cycle need available start next cohort .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics Anti-tumor Activity Sorafenib Eribulin Combination</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Subjects advance , metastatic refractory solid malignancy candidate standard therapy . For subject metastatic breast cancer , prior therapy include anthracycline taxane either adjuvant metastatic setting . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bone marrow , cardiac , liver , renal pancreatic function Predicted life expectancy least 12 week Prolonged correct QT ( QTc ) , define QTcF ( QT interval correct heart rate accord Fridericia ) interval &gt; 450 msec screen central reader Cardiac disease : Congestive heart failure &gt; NYHA Class II ; subject must unstable angina ( angina symptom rest ) newonset angina ( begin within last 3 month ) myocardial infarction within past 6 month ; cardiac ventricular arrhythmia require antiarrhythmic therapy Arterial venous thrombus , include cerebrovascular accident myocardial infarction past 6 month Pulmonary hemorrhage event ≥ CTCAE ( common toxicity criterion adverse event ) Grade 2 within 4 week Any hemorrhage/bleeding event ≥ CTCAE Grade 3 within 4 week Chemotherapy , hormonal therapy , investigational drug , radiotherapy within last 28 day and/or recover ( &lt; Grade 1 ) prior therapy . Start study treatment allow within less 28 day prior therapy provide 5 halflives prior treatment drug ( ) elapse . Use medication may prolong QTc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Clinical benefit</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Eribulin</keyword>
	<keyword>advanced metastatic solid tumor</keyword>
</DOC>